Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;66(6):1321-1322.
doi: 10.1007/s10840-023-01548-2. Epub 2023 Apr 26.

Transient left bundle branch block associated with favipiravir treatment for coronavirus infection

Siralp Bostan  1 , Gizem Vural  2 , Dilara Ecren Alaeddinoğlu  2 , Ferit Onur Mutluer  3 , Henry Huang  4 , Tolga Aksu  5
Affiliations

Transient left bundle branch block associated with favipiravir treatment for coronavirus infection

Siralp Bostan et al. J Interv Card Electrophysiol. 2023 Sep.

Abstract

The coronavirus disease 2019 (COVID-19) may lead to a wide spectrum of clinical manifestations ranging from asymptomatic to symptomatic by having targets on various tissues such as lung parenchyma and myocardium (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). As an RNA-dependent RNApolymerase inhibitor, favipiravir has been proposed as a treatment in clinical studies done during the pandemic period (Furuta et al., Antiviral Res. 100(2):446-454, 2013). Although favipiravir is generally a safe medication, it may rarely cause cardiac adverse effects (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). To the best of our knowledge, favipiravir has not been reported to cause left bundle branch block (LBBB).

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
A Admission ECG showing normal sinus rhythm and QRS complexes. B Remarkable presentation on ECG with transient LBBB
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Favipiravir-induced bradycardia: A case report.
    Kashefizadeh A, Ohadi L, Amiri F, Abdolmaleki M, Eslami V, Jafari Fesharaki M. Kashefizadeh A, et al. Clin Case Rep. 2024 Jun 27;12(7):e9052. doi: 10.1002/ccr3.9052. eCollection 2024 Jul. Clin Case Rep. 2024. PMID: 38947534 Free PMC article.

References

    1. Shahrbaf MA, Tabary M, Khaheshi I. Cardiovascular considerations of remdesivir and favipiravir in the treatment of COVID-19. Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88–90. doi: 10.2174/1871529X21666210812103535. - DOI - PubMed
    1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454. doi: 10.1016/j.antiviral.2013.09.015. - DOI - PMC - PubMed
    1. Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017;11(12):e0006034. doi: 10.1371/journal.pntd.0006034. - DOI - PMC - PubMed
    1. Habib MB, Elshafei M, Rahhal A, Mohamed MFH. Severe sinus bradycardia associated with favipiravir in a COVID-19 patient. Clin Case Rep. 2021;9(8):e04566. doi: 10.1002/ccr3.4566. - DOI - PMC - PubMed